C.R. Jackson
Biotech, healthcare, value, research analyst

Near A 52-Week Low, Is OncoGenex Pharmaceuticals A Buy?

Approximately 90% of cancer patients with metastatic breast, prostate, lung or colon cancers develop resistance to chemotherapy. Despite scientific advances, cancer treatment failure due to treatment resistance is a major problem in oncology.

OncoGenex Pharmaceuticals Inc. (OGXI) has focused its efforts on the development of therapeutics that target important mechanisms of cancer treatment resistance with the potential to improve treatment outcomes for patients with a variety of cancers.

The company was established in May 2000 as a spin-out from the Prostate Centre at Vancouver General Hospital and the University of British Columbia. It was co-founded by urologist Martin Gleave, MD, and Scott Cormack, OncoGenex' President and CEO, initially to develop and commercialize custirsen (OGX-011), which was discovered at...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
PRO Top long ideas returned 21.7% in 2016**
"As a PRO member, we get uniquely valuable perspective that go beyond our quantiative analysis... We rely on PRO to get beyond the numbers quickly and add much needed perspective. It keeps me ahead of the next big thing. - Mark Choate, Malaga Cove Capital"
Mark Choate, Malaga Cove Capital
"Contributors (writers and commentators), often have a long history in the secuirities they opine on and some are clearly well positioned industry participants with detailed industry views that can help provide color on where the skeletons are buried in a particular secuirity and/or industry."
Jim Roumell, Roumell Asset Management
Annual subscriptions may be cancelled for any reason within the first 30 days and receive a full and prompt refund. Details